When it comes to pharmacology, the big story these days is the development of the “glucagon-like peptide-1 (GLP-1) mimics,” ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

Weight loss specialist Dr Gerard McQuinlan also believed that funding Wegovy would save the taxpayer money in the long run. He told RNZ that obesity was related to more than 200 other diseases. “If I ...

Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal ...

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S. FDA is acknowledging that the drugs don’t have the same risk seen with older weight-loss ...

The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased ...

The warnings, part of their original approval, were based ​on reports of such events observed with a variety of older ...